It's been nearly a month since Ironwood Pharmaceuticals Inc. tested the biotech initial public offering waters, and now three more biotechs are queued up to price IPOs over the next three weeks. (BioWorld Today)

Cephalon Inc.'s recent $590 million purchase of Swiss generics player Mepha AG was intended to create a balanced portfolio of branded products and generics.

Tioga Pharmaceuticals Inc. raised $18 million in its second round of venture financing, money that will allow the San Diego biotech to complete a Phase III trial with asimadoline for diarrhea predominant irritable bowel syndrome (D-IBS). (BioWorld Today)